Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2379)
All Articles published online
|
Aug 28, 2007 (publication date) through Apr 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Moshkovska T, Mayberry J. Duration of treatment with 5-aminosalicylic acid compounds. World J Gastroenterol 2007; 13(32): 4310-4315 [PMID: 17708602 DOI: 10.3748/wjg.v13.i32.4310] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v13/i32/4310.htm |
| Number | Citing Articles |
| 1 |
T. MOSHKOVSKA, M. A. STONE, J. CLATWORTHY, R. M. SMITH, J. BANKART, R. BAKER, J. WANG, R. HORNE, J. F. MAYBERRY. An investigation of medication adherence to 5‐aminosalicylic acid therapy in patients with ulcerative colitis, using self‐report and urinary drug excretion measurements. Alimentary Pharmacology & Therapeutics 2009; 30(11-12): 1118 doi: 10.1111/j.1365-2036.2009.04152.x
|
| 2 |
Reena Khanna, Brian G Feagan. Ustekinumab for the treatment of Crohn’s disease. Immunotherapy 2013; 5(8): 803 doi: 10.2217/imt.13.81
|
| 3 |
Reena Khanna, John K. Marshall. Crohn's Disease and Ulcerative Colitis. 2017; : 389 doi: 10.1007/978-3-319-33703-6_38
|
| 4 |
H. Mayberry, T. Moshkovska, J. F. Mayberry. Co-prescribing azathiopurine or 6-mercaptopurine and 5-aminosalicylate compounds in ulcerative colitis. Inflammatory Bowel Diseases 2009; 15(2): 190 doi: 10.1002/ibd.20750
|
| 5 |
Ryan C Ungaro, Harisha Kadali, Wenwen Zhang, Shashi Adsul, Walter Reinisch. Impact of Concomitant 5-Aminosalicylic Acid Therapy on Vedolizumab Efficacy and Safety in Inflammatory Bowel Disease: Post Hoc Analyses of Clinical Trial Data. Journal of Crohn's and Colitis 2023; 17(12): 1949 doi: 10.1093/ecco-jcc/jjad113
|
| 6 |
Lisa J. Herrinton, Liyan Liu, Bruce Fireman, James D. Lewis, James E. Allison, Nicole Flowers, Susan Hutfless, Fernando S. Velayos, Oren Abramson, Andrea Altschuler, Geraldine S. Perry. Time Trends in Therapies and Outcomes for Adult Inflammatory Bowel Disease, Northern California, 1998–2005. Gastroenterology 2009; 137(2): 502 doi: 10.1053/j.gastro.2009.04.063
|
| 7 |
Affifa Farrukh, John F Mayberry. Surveillance for colorectal cancer and chemoprevention in ulcerative and Crohn's colitis: The need for clinical strategies to increase effectiveness. JGH Open 2019; 3(5): 370 doi: 10.1002/jgh3.12173
|
| 8 |
Zunwu Zhang, Hugh Kennedy. Ulcerative colitis: current medical therapy and strategies for improving medication adherence. European Journal of Gastroenterology & Hepatology 2009; 21(1): 1 doi: 10.1097/MEG.0b013e32830bfb88
|
| 9 |
Reena Khanna, John K. Marshall. Crohn's Disease and Ulcerative Colitis. 2012; : 453 doi: 10.1007/978-1-4614-0998-4_36
|
| 10 |
Hiroaki Ito, Shigeru Furuta, Hidetaka Sasaki, Toyomitsu Yoshida, Yuichi Takano, Toshifumi Hibi. Pharmacokinetics and safety of single and multiple doses of Asacol tablets in Japanese healthy volunteers. Advances in Therapy 2009; 26(8): 749 doi: 10.1007/s12325-009-0059-9
|
| 11 |
Stefan Schreiber, Michael A Kamm, Gary R Lichtenstein. Mesalamine with MMX™ technology for the treatment of ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2008; 2(3): 299 doi: 10.1586/17474124.2.3.299
|
| 12 |
Anita Annaházi, Tamás Molnár. Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal. Gastroenterology Research and Practice 2015; 2015: 1 doi: 10.1155/2015/832395
|